These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 14689108

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
    Wald DS, Law M, Mills S, Bestwick JP, Morris JK, Wald NJ.
    Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
    [Abstract] [Full Text] [Related]

  • 26. RAS inhibition in hypertension.
    Ibrahim MM.
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [Abstract] [Full Text] [Related]

  • 27. [Fewer cases of stroke, atrial fibrillation, diabetes and renal insufficiency. Good treatment of hypertension is more than lowering of blood pressure].
    Baumgart P.
    MMW Fortschr Med; 2008 Jan 17; 150(1-2):52-3. PubMed ID: 18300647
    [No Abstract] [Full Text] [Related]

  • 28. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA, McAlister FA, Lewanczuk RZ, Touyz RM, Padwal R, Rabkin SW, Leiter LA, Lebel M, Herbert C, Schiffrin EL, Herman RJ, Hamet P, Fodor G, Carruthers G, Culleton B, DeChamplain J, Pylypchuk G, Logan AG, Gledhill N, Petrella R, Campbell NR, Arnold M, Moe G, Hill MD, Jones C, Larochelle P, Ogilvie RI, Tobe S, Houlden R, Burgess E, Feldman RD, Canadian Hypertension Education Program.
    Can J Cardiol; 2005 Jun 17; 21(8):657-72. PubMed ID: 16003449
    [Abstract] [Full Text] [Related]

  • 29. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y, Tsuchihashi T, Onaka U, Eto K, Ueno M.
    Hypertens Res; 2007 Apr 17; 30(4):301-6. PubMed ID: 17541208
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes.
    Roca-Cusachs A, Schmieder RE, Triposkiadis F, Wenzel RR, Laurent S, Kohlmann O, Fogari R, MORE Study Group.
    J Hypertens; 2008 Apr 17; 26(4):813-8. PubMed ID: 18327093
    [Abstract] [Full Text] [Related]

  • 35. Benefits of angiotensin converting enzyme inhibition and angiotensin II receptor antagonists in hypertension.
    Conlin PR.
    J Med Liban; 2000 Apr 17; 48(6):382-6. PubMed ID: 11503531
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. AT1 receptor blockers--cost-effectiveness within the South African context.
    Anderson AN, Wessels F, Moodley I, Kropman K.
    S Afr Med J; 2000 May 17; 90(5):494-8. PubMed ID: 10901822
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.